Logo

Biomea Fusion, Inc.

BMEA

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was… read more

Healthcare

Biotechnology

5 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.20

Price

+2.57%

$0.03

Market Cap

$86.759m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$44.950m

+27.3%

1y CAGR

+21.5%

3y CAGR

+5.3%

5y CAGR
EPS

-$0.89

+24.6%

1y CAGR

+27.5%

3y CAGR

+14.9%

5y CAGR
Book Value

$18.719m

$46.385m

Assets

$27.666m

Liabilities

$1.239m

Debt
Debt to Assets

2.7%

-

Debt to EBITDA
Free Cash Flow

-$56.248m

+20.1%

1y CAGR

+13.8%

3y CAGR

-4.1%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases